Cboe Global Markets heads into its third-quarter report with the stock pressing against its post-earnings high and a management team that has spent the past year raising the bar on itself. Organic revenue guidance has climbed from mid-single digits to mid-to-high teens in three steps, margins hit a record last quarter, and the company has shifted from pruning its portfolio to launching new products. The October 30 release, due before the open, is the first real test of whether that offense-minded story still has room to run.

Wall Street expects GAAP earnings of $3.40 a share, up 27.3% from $2.67 a year ago, on revenue of roughly $702 million. The projected 38.5% revenue decline looks alarming but appears to reflect a difference in basis: the year-ago total included pass-through costs, while the consensus figure lines up with net revenue, which was about $605 million in the year-ago quarter. Measured that way, the Street is modeling growth in the mid-teens, broadly consistent with management's mid-to-high-teens organic outlook. Note the sequential picture, too. Consensus sits below the record $732 million in net revenue and slightly under last quarter's $3.48 in GAAP EPS, partly because the Australia sale closed in the quarter and strips out roughly $20 million in annual net revenue. Clean organic numbers will matter more than the headline.

The core of the bull case is the derivatives franchise. Index options volume grew 32% last quarter, SPX zero-day options set records, and the June repeal of the Pattern Day Trader Rule produced a quick jump in retail activity, with retail's share of zero-day SPX volume rising to 57%. The key question is whether that surge was a one-month sugar high or a structural step up. Sustained strength in SPX and mini-SPX volumes through the summer would validate the second guidance raise and keep the door open for a third. A fade back toward pre-repeal levels would suggest the June spike flattered the run rate. Futures remains the weak link after net revenue growth slowed to just 2%, and further deceleration would undercut the claim that growth has broadened across all five segments.

The newer catalysts deserve scrutiny even though none of them is in the 2026 guidance. Company-specific KPI event contracts, with Schwab lined up as an anchor partner for XSP binaries, were targeted for a late-September or early-October launch, so this call should reveal whether approval arrived on schedule and how early volumes look. Progress on the Cboe Clear US registration, readiness for 23x5 equities trading in December, and any update on the Canada sale will also shape the narrative. On the cost side, capital spending guidance already jumped to $98 million to $108 million for the clearing build, so margins near last quarter's 72% would show expense discipline holding up while the company invests. Buyback pace and planning for the $650 million debt maturing early next year round out the capital story.

Expectations have warmed considerably. Sentiment has swung from decidedly bearish before the last report to moderately bullish now, and the shares have gained about 11% since then, beating the S&P 500 by roughly 7 points. At about $319, the stock trades well above its 200-day average near $290 and sits within a whisker of its $320 post-earnings high, a level that a convincing report could push it through. The trading range has also narrowed sharply from the prior quarter's swings between $227 and $371, suggesting a calmer, more confident tape.

That confidence raises the stakes. With guidance lifted repeatedly and the stock at the top of its range, a merely in-line quarter may not satisfy. The narrative stays intact if retail-driven options volume proved durable after June and management can point to tangible traction in event contracts. If volumes cooled and the new products slipped, the market may conclude that the easy gains are already priced in.